Business Description
BeiGene Ltd
NAICS : 325412
SIC : 2834
ISIN : KYG1146Y1017
Share Class Description:
HKSE:06160: Ordinary SharesCompare
Compare
Traded in other countries / regions
688235.China06160.Hong KongBGNE.USA49B.GermanyB1GN34.BrazilBGNE.Mexico IPO Date
2018-08-08Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.41 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.83 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 3.21 | |||||
| Beneish M-Score | -1.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 85.3 | |||||
| 3-Year EBITDA Growth Rate | 18 | |||||
| 3-Year EPS without NRI Growth Rate | 24.3 | |||||
| 3-Year FCF Growth Rate | 2.4 | |||||
| 3-Year Book Growth Rate | -7.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 25.01 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.05 | |||||
| 9-Day RSI | 72.02 | |||||
| 14-Day RSI | 62.71 | |||||
| 6-1 Month Momentum % | -17.83 | |||||
| 12-1 Month Momentum % | -41.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.32 | |||||
| Quick Ratio | 2.09 | |||||
| Cash Ratio | 1.75 | |||||
| Days Inventory | 313.91 | |||||
| Days Sales Outstanding | 43.03 | |||||
| Days Payable | 280.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.5 | |||||
| Shareholder Yield % | -0.17 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.55 | |||||
| Operating Margin % | -49.12 | |||||
| Net Margin % | -35.86 | |||||
| FCF Margin % | -71.37 | |||||
| ROE % | -22.45 | |||||
| ROA % | -15 | |||||
| ROIC % | -60.1 | |||||
| ROC (Joel Greenblatt) % | -103.23 | |||||
| ROCE % | -27.23 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.94 | |||||
| PB Ratio | 4.8 | |||||
| Price-to-Tangible-Book | 4.95 | |||||
| EV-to-EBIT | -12.78 | |||||
| EV-to-Forward-EBIT | -13.85 | |||||
| EV-to-EBITDA | -13.78 | |||||
| EV-to-Forward-EBITDA | -15.22 | |||||
| EV-to-Revenue | 6.28 | |||||
| EV-to-Forward-Revenue | 5.31 | |||||
| EV-to-FCF | -8.8 | |||||
| Price-to-Net-Current-Asset-Value | 8.77 | |||||
| Price-to-Net-Cash | 18.73 | |||||
| Earnings Yield (Greenblatt) % | -7.82 | |||||
| FCF Yield % | -9.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BeiGene Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 19,248.412 | ||
| EPS (TTM) (HK$) | -5.169 | ||
| Beta | 0.62 | ||
| Volatility % | 44.7 | ||
| 14-Day RSI | 62.71 | ||
| 14-Day ATR (HK$) | 3.62925 | ||
| 20-Day SMA (HK$) | 87.8825 | ||
| 12-1 Month Momentum % | -41.65 | ||
| 52-Week Range (HK$) | 75.45 - 157 | ||
| Shares Outstanding (Mil) | 1,359 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BeiGene Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BeiGene Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BeiGene Ltd Frequently Asked Questions
What is BeiGene Ltd(HKSE:06160)'s stock price today?
The current price of HKSE:06160 is HK$97.75. The 52 week high of HKSE:06160 is HK$157.00 and 52 week low is HK$75.45.
When is next earnings date of BeiGene Ltd(HKSE:06160)?
The next earnings date of BeiGene Ltd(HKSE:06160) is 2024-08-02 Est..
Does BeiGene Ltd(HKSE:06160) pay dividends? If so, how much?
BeiGene Ltd(HKSE:06160) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers